Equity Analyst Action: Dendreon, P&G, TriMas, Cavium
Dendreon Corp. (NASDAQ:DNDN): Citigroup believes demand for Dendreon’s Provenge remains questionable following the company’s Q4 results and keeps a Neutral rating on the stock. After Dendreon reported Q4 results, Brean Murray expressed its confidence that the company will not be profitable until 2015 at the earliest. The firm says it is difficult to see how Dendreon survives longer term with competition coming from oral drugs and keeps a Sell rating on the stock with a $6 price target.
Procter & Gamble (NYSE:PG): BMO Capital upgraded Procter & Gamble citing the announcement of its $10B savings program that addresses internal productivity and its corporate structure. Price target raised to $78 from $68
TriMas Corporation(NASDAQ:TRS): Barrington raised its price target for TriMas shares following the company’s Q4 results and reiterates an Outperform rating on the stock.
Cavium Networks, Inc.(NASDAQ:CAVM): Cavium Networks named a long Research Tactical Idea at Morgan Stanley
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at email@example.com
To contact the editor responsible for this story: Damien Hoffman at firstname.lastname@example.org